Anti-HLA immunization of patients qualified for lung transplantation – Single center study

• Published in: Transplant immunology 2022-04, Vol.71, p.101553-101553, Article 101553
• Main Authors: Karolak, Wojtek, Dukat-Mazurek, Anna, Woźniak-Grygiel, Elżbieta, Łącka, Monika, Wojarski, Jacek, Moszkowska, Grażyna, Dębska-Zielkowska, Joanna, Zielińska, Hanna, Łukaszewska, Joanna, Sharma, Naivedya, Lango-Maziarz, Anna, Maruszewski, Marcin, Żegleń, Sławomir
• Format: Article
• Language: English
• Subjects: Anti-HLA sensitization; Graft Rejection - diagnosis; Histocompatibility Testing; HLA Antigens; Humans; Immunization; Isoantibodies; Kidney Transplantation; Lung Transplantation; Retrospective Studies; Transplant immunology
• ISSN: 0966-3274; 1878-5492
• DOI: 10.1016/j.trim.2022.101553

For lung transplantation, the presence of donor-specific anti-HLA antibodies (DSA) is an important factor of antibody-mediated rejection (AMR) in its hyperacute, acute or chronic form during long-term follow up. The aim of the study was to assess the allosensitization of Polish patients qualified for a lung transplantation in our center. A retrospective study of 161 potential lung allograft recipients, also of 31 patients transplanted in the University Hospital of Gdansk, between June 2018 and December 2020 were performed. 121 potential recipients were thoroughly tested for immunization status before eventual lung transplantation. SAB-testing, PRA-CDC and vPRA assessment, and HLA typing were performed to guide donor-recipient matching and risk stratification. Then 73 patients were separated and qualified for the list of patients awaiting lung transplantation. Then 31 patients were transplanted based on a negative biological crossmatch result. The patients were generally not sensitized, as the median PRA-CDC was 0% (min 0; max 53), and the vPRA, calculated according to HLA ABDR (>2000 cut-off MFI), was 8% (min 0; max 99). If the cut-off was split into 2000 MFI for HLA ABDR, 10,000 MFI for HLAC, and 7000 MFI for HLA-DQ, the vPRA increased to 20% (min 0; max 99). The immunization status was assessed with single antigen-SAB assays. For class I, the number of any detectable alloantibodies was 14 (11.6%) 21 (17.35%) 16 (13.22%) for locus HLA-A/B/C, and 28 (23.14%) 30 (24.8%) 24 (19.8%) for locus HLA-DR/DQ/DP, respectively. The immunization of the transplanted patients was then analyzed in detail. Summarizing, the study is an analysis of the degree of anti-HLA immunization in the population of patients eligible for lung transplantation, which showed that this degree is of low intensity and can be effectively and safely and very precisely diagnosed before transplantation.